Ovarian cancer side population defines cells with
stem cell-like characteristics and Mullerian Inhibiting
Paul P. Szotek*, Rafael Pieretti-Vanmarcke*, Peter T. Masiakos*, Daniela M. Dinulescu†, Denise Connolly‡,
Rosemary Foster§, David Dombkowski¶, Frederic Preffer¶, David T. MacLaughlin*, and Patricia K. Donahoe*?
*Pediatric Surgical Research Laboratories, Department of Surgery, and¶Flow Cytometry Laboratory, Department of Pathology and Center for Regenerative
Medicine, Massachusetts General Hospital, Harvard Medical School, 185 Cambridge Street, Boston, MA 02114;‡Fox Chase Cancer Center, 7701 Burholme
Avenue, Philadelphia, PA 19111;†Department of Pathology, Eugene Braunwald Research Center, Brigham and Women’s Hospital, Harvard Medical School,
221 Longwood Avenue, Room 401a, Boston, MA 02115; and§Department of Medicine, Division of Hematology?Oncology, Massachusetts General Hospital,
Harvard Medical School, 70 Blossom Street, Boston, MA 02114
Contributed by Patricia K. Donahoe, May 4, 2006
of unrelated human cancers and their normal tissue sources has
renewed interest in the hypothesis that cancers may arise from
somatic stem?progenitor cells. The high incidence of recurrence
attributable to multidrug resistance and the multiple histologic
phenotypes indicative of multipotency suggests a stem cell-like
etiology of ovarian cancer. Here we identify and characterize SP
cells from two distinct genetically engineered mouse ovarian
cancer cell lines. Differential efflux of the DNA-binding dye
Hoechst 33342 from these cell lines defined a human breast
cancer-resistance protein 1-expressing, verapamil-sensitive SP of
candidate cancer stem cells. In vivo, mouse SP cells formed mea-
surable tumors sooner than non-SP (NSP) cells when equal num-
bers were injected into the dorsal fat pad of nude mice. The
presence of Mullerian Inhibiting Substance (MIS) signaling path-
way transduction molecules in both SP and NSP mouse cells led us
to investigate the efficacy of MIS against these populations in
comparison with traditional chemotherapies. MIS inhibited the
proliferation of both SP and NSP cells, whereas the lipophilic
chemotherapeutic agent doxorubicin more significantly inhibited
1-expressing verapamil-sensitive SPs in three of four human ovar-
ian cancer cell lines and four of six patient primary ascites cells. In
the future, individualized therapy must incorporate analysis of the
therapeutic strategies for ovarian cancer patients.
cancer stem cells ? breast cancer-resistance protein 1
gastrointestinal tumors, and retinoblastoma, were shown to possess
cells (1–5). Cancer stem cells, like somatic stem cells, are thought
to be capable of unlimited self-renewal and proliferation. Multipo-
tent cancer stem cells may explain the histologic heterogeneity
often found in tumors (6–9). In addition, cancer progression and
metastasis may involve tumor stem cell escape from innate somatic
niche regulators. Quiescent somatic stem cells residing in specific
tissue niches until activation by injury or other stimuli have been
other organs (10). The evolving evidence that somatic stem cells
contribute to normal tissue repair and regeneration suggests the
for regulated surface epithelial repair after ovulatory rupture and
possibly the generation of oocyte nurse cells for folliculogenesis
(11). Ovarian somatic stem cells would be expected to divide
asymmetrically, yielding both a daughter cell that proceeds to
terminal differentiation for epithelial repair and an undifferenti-
ated self-copy. Repeated asymmetric self-renewal sets the stage for
ecently, two human primary cancers, leukemia and breast, and
somatic stem cells or their immediate progenitors to accrue mu-
tations over time, which might ultimately lead to their transforma-
tion into cancer stem cells and malignant progression.
Epithelial ovarian cancer, thought to emanate from the surface
epithelium of the ovary (12, 13), consists of various histologic
affects ?22,000 women in North America per year, and accounts
for ?16,000 deaths per year with a projected 5 year mortality rate
exceeding 70% (14). Aggressive surgical cytoreduction followed by
chemotherapy results in complete clinical response in 50–80% of
patients with stage III and IV disease. However, the majority of
patients will relapse and become drug-resistant (14–16). Various
types of membrane-spanning ATP-binding cassette transporters,
such as the multidrug-resistant gene 1 and breast cancer-resistance
protein 1 (BCRP1), contribute to the drug resistance of many
cancers, including ovarian cancer, by pumping lipophilic drugs out
of the cell (17). Within bone marrow, researchers have defined a
subset of verapamil-sensitive BCRP1-expressing cells with the
ability to efflux the lipophilic dye Hoechst 33342. This subset has
been described as the SP (18). The functional and phenotypic
availability of tumor cells in ascites permits their study by flow
Here we show that distinct histologic types of genetically engi-
neered mouse ovarian cancer cells (MOVCAR 7 and 4306) have a
proportionately large SP, making them a model to study ovarian
cancer stem cell biology. A similar, albeit very small, SP was also
identified in human ovarian cancer cell lines (IGROV-1, SK-OV3,
and OVCAR-3) and in patient primary ascites cells. We used the
MOVCAR 7 cell line to demonstrate that SP cells can reconstitute
colonies in vitro, form tumors earlier than NSP cells in vivo, and
remain responsive to Mullerian Inhibiting Substance (MIS). Our
cancer stem cells and that one of the advantages of MIS may be its
as compared with the lipophilic chemotherapeutic doxorubicin,
which more effectively inhibited the NSP. These findings, if cor-
roborated in further studies of human specimens, may provide an
explanation for the ability of transporter substrates such as anthra-
cyclines to cytoreduce but essentially never cure recurrent ovarian
cancer. More importantly, identification of the ovarian cancer stem
Conflict of interest statement: No conflicts declared.
Abbreviations: BCRP1, human breast cancer-resistance protein 1; Bcrp1, mouse breast
cancer-resistance protein 1; MIS, Mullerian Inhibiting Substance; MISRII, MIS type II recep-
tor; MTT; methylthiazoletetrazolium; NSP, non-SP; SP, side population.
whom correspondence shouldbe addressed. Email:donahoe.patricia@mgh.
© 2006 by The National Academy of Sciences of the USA
July 25, 2006 ?
vol. 103 ?
no. 30 www.pnas.org?cgi?doi?10.1073?pnas.0603672103
cell would provide a critical step in advancing the development of
novel therapeutic strategies in the management of this disease.
Identification of SPs in Mouse Ovarian Cancer Cell Lines. To deter-
mine whether mouse ovarian cancer cell lines contain candidate
cancer stem cells, Hoechst 33342 was used to sort for the SP
phenotype. The serous adenocarcinoma-recapitulating MOVCAR
7 and 8 cell lines were developed by using the MIS type II receptor
(MISRII) promoter to drive the SV40 T antigen (19). The endo-
metrioid carcinoma-recapitulating 4306 cell line was developed
from conditional LSL-K-rasG12D/??PtenloxP/loxPmice in which the
Cre recombinase (20). Flow cytometry demonstrated a very high
lines (Fig. 1 A and B), whereas SP was not detected in MOVCAR
in both MOVCAR 7 and 4306 cells (Fig. 1 C and D). The average
first sort percentage of SP cells was 6.28% (n ? 6) for MOVCAR
7 and 1.83% (n ? 4) for 4306 cells, which is elevated relative to the
SP found in other somatic and malignant sources (3, 18, 21).
Colocalization of HoechstLowand Bcrp1 immunoreactive MOV-
CAR 7 and 4306 cells confirmed the presence of SP cells (Fig. 1
(data not shown). Thus, MOVCAR 7 and 4306 cells possess SPs
with Hoechst efflux characteristics reminiscent of those defined in
hematopoietic stem cells.
Ex Vivo Growth of SP and NSP Cells. GrowthcharacteristicsoftheSP
and NSP cells were consistent with previous findings for cancer
stem cells (21). MOVCAR 7 and 4306 cells were sorted by flow
with a cobblestone appearance and survived numerous passages
(Fig. 2 A and C; n ? 9). NSP cells from both cell lines were sparse
and failed to proliferate beyond 1–2 weeks (Fig. 2 B and D; n ? 9).
These differences were not a consequence of prolonged Hoechst
retention in the NSP cells because propidium iodide was used to
gate out all nonviable cells. Serial sorting and reanalysis (total
passages ? 3) of SP cells demonstrated enrichment of the SP and
the presence of NSP cells (Fig. 2 E–J), suggesting asymmetric
are able to self-renew, be enriched, and produce NSP cells when
recovered and serially sorted in culture.
SP Cells Are in G1Cell Cycle Arrest and Resistant to Doxorubicin in
Vitro. By definition, SP cells should express high levels of BCRP1
and thus be able to efflux the lipophilic dye Hoechst 33342 and
some lipophilic anticancer drugs, including those used in the
doxorubicin is a substrate of the BCRP1 transporter, whereas the
MOVCAR 7 and 4306 cell lines were labeled with Hoechst 33342 dye and
analyzed by flow cytometry before (A and B) and after (C and D) treatment
Brcp1 immunoreactivity and Hoechst dye uptake. HoechstLowcells (E and F;
dashed circle and arrows) show Bcrp1 immunoreactivity (G and H; arrows).
HoechstLowcells colocalize with Bcrp1-positive cells (I and J; arrows).
?10 phase-contrast microscope. SP cells from both cell lines form tight colonies after 4 days in culture, whereas NSP cells are scattered and do not proliferate.
MOVCAR 7- and 4306-sorted SP cells (E and H) were cultured for 7–10 days, resorted by flow cytometry (F and I), recovered for an additional 7–10 days, and then
reanalyzed by flow cytometry (G and J). Each successive sort demonstrated the enrichment of SP cells and the presence of NSP cells.
Szotek et al.
July 25, 2006 ?
vol. 103 ?
no. 30 ?
the functional significance of the Bcrp1 transporter found in
MOVCAR 7 SP cells, we tested their response to doxorubicin and
paclitaxel, as compared with that observed in the NSP, by meth-
ylthiazoletetrazolium (MTT) proliferation assays (Fig. 3).
MOVCAR 7 SP cells were only inhibited by 30% after treatment
with doxorubicin, whereas the NSP cells showed 81% inhibition
3B; SP ? 85% inhibition; NSP ? 83% inhibition).
Quiescence is one of the defining characteristics of somatic
stem cells (24). Cell cycle analysis of three sorted populations,
HoechstLowSP, HoechstMidNSP, and HoechstHighNSP (Fig. 3C),
revealed that the HoechstMidand HoechstHighNSP cells had a
higher percentage of cells in S phase (Fig. 3 D and E), compared
with HoechstLowSP (Fig. 3F). In contrast, HoechstLowSP cells
demonstrate a predominance of cells in the G1phase (Fig. 3F)
In Vivo Growth Characteristics of MOVCAR 7 SP and NSP Cells. To
assess in vivo tumorgenicity of MOVCAR 7 SPs and NSPs, viable
propidium iodide-negative SP and NSP cells were sorted and
injected into the dorsal fat pad of nude mice (Fig. 4A and Table 1,
which is published as supporting information on the PNAS web
site). Tumors appeared in three of three animals at 10 weeks after
injection of 5.0 ? 105SP cells, whereas animals injected with an
at that time (Fig. 4B). Tumors appeared in two of three of the NSP
injected with 7.5 ? 105SP cells, whereas NSP-injected animals had
after 10 weeks in two of three animals (Table 1). To investigate
whether the appearance of tumors in the NSP could possibly be
explained by incomplete sorting, we reanalyzed the sorted popu-
4C; NSP contamination ? 2.63% or ?13,150 SP cells in a total of
5 ? 105cells per animal; 19,750 SP cells in a total of 7.5 ? 105cells
per animal) and 92.3% NSP cell purity (Fig. 4D; SP contamina-
tion ? 1.72% or ?8,600 SP cells in 5 ? 105cells per animal; 12,900
SP cells in 7.5 ? 105cells per animal). In addition, the NSP tumors
dissected from animals at euthanization showed verapamil-
sensitive SP cells (Fig. 4 E and F), suggesting that SP cells have the
potential to initiate earlier tumor growth at lower numbers. In a
parallel experiment, preinjection analysis demonstrated an SP
fraction equal to 0.21% (?12,600 SP cells per animal) of the 6 ?
106unsorted cells per animal injected into 50 nude mice (data not
shown). The average time to appearance of these tumors was ?9
weeks; in close agreement with our 7.5 ? 105NSPs (?12,900 SP
small population of SP cells has the potential to initiate tumor
growth in vivo.
MOVCAR 7 and 4306 SP Cells Respond to MIS in Vitro. MIS has been
shown to inhibit MOVCAR 7 both in vitro and in vivo (25). Thus,
we investigated whether MIS inhibits MOVCAR 7 and 4306 SP
and?or NSP cells in vitro. We first confirmed that SP and NSP cells
possess an intact MIS signal transduction pathway, previously
shown to be required for MIS responsiveness in the embryonic
urogenital ridge (26). By using anti-MISRII antibody we observed
that MOVCAR 7 and 4306 cells express the MISRII receptor by
epifluorescent and confocal microscopy (Fig. 5 B and C; 4306 cells
cycle arrest. MOVCAR 7 cells were sorted for MTT growth-inhibition analysis
against doxorubicin and paclitaxel. SP cells showed 30% inhibition (A) by
doxorubicin (*, P ? 4.2 ? 10?4) and 85% inhibition (B) by paclitaxel (*, P ?
6.7 ? 10?10) compared with vehicle-treated controls. NSP cells were inhibited
more inhibited by doxorubicin than by SP cells (81% versus 30% growth
inhibition;***, P ? 1.6 ? 10?9). Cell cycle analysis of three populations was
performed as shown in C. HoechstHighNSP and HoechstMidcells (D and E)
(average ? 51.5%), respectively, and decreased G1-arrested cells, 23% (aver-
age ? 53%) and 15.9% (average ? 39%), compared with HoechstLowSP cells
[P ? 0.0407 (F)]. HoechstLowSPs demonstrate a predominance of G1-arrested
cells, 63% (average ? 65.8%), and decreased S phase replicating cells, 33.4%
(30.57%). All experiments were performed in triplicate.
SP cells demonstrate decreased inhibition by doxorubicin and G1cell
105cells per animal (data not shown)]. Measurable tumors were detected in
SP-injected group I animals at 10 weeks (three of three) (B) and SP-injected
of three) (B) and group II NSP-injected animals did not demonstrate tumors at
in group I and II NSP tumors until 14 and 11 weeks after injection. Sorting
purity analysis (C and D) showed an ?93% purity in both SP and NSP sorts,
identifying contamination by NSP sorts with SP cells. NSP tumors harvested
after euthanization revealed the presence of a verapamil-sensitive SP of
www.pnas.org?cgi?doi?10.1073?pnas.0603672103Szotek et al.
not shown). We then confirmed the presence of MISRII, MISRI
(Alk 2 and 3), and Smad 1?5?8 mRNA by RT-PCR in sorted SP
and NSP cells (SP in Fig. 5D; NSP and 4306 cells are the same but
not shown), suggesting these cells would likely respond to MIS.
MOVCAR 7 and 4306 SP and NSP cells were sorted, incubated
for 24 h, and treated with 10 ?g?ml MIS for MTT proliferation
assays. MOVCAR 7 SP and NSP cells responded to MIS after
initial sorting of the neat population. MOVCAR 7 SP cells were
inhibited by 86%, whereas NSP cells were inhibited by 93%
cells showed a significant inhibition of 37% by MIS (Fig. 7, which
is published as supporting information on the PNAS web site)
However, because NSP cells could not reliably be maintained in
culture for serial sorting, we evaluated the ability of MIS to inhibit
the SP alone after enrichment in both cell lines. MOVCAR 7 serial
sorting followed by MTT showed 93% inhibition after sort 2 and
94% inhibition after sort 3 (Fig. 5 F and G). Serial sorting of 4306
cells followed by MTT showed 60% inhibition after sort 2 (Fig. 7),
and no inhibition after sort 3 was observed (17% inhibition; P ?
0.054). Thus, MIS inhibits MOVCAR 7 and 4306 SP cells in vitro.
Human Ovarian Cancer Cell Lines and Primary Patient Ascites Cells
cancer, we evaluated the cell lines OVCAR 3, OVCAR 8, SK-
OV-3, and IGROV-1, as well as ascites from six ovarian cancer
patients (see cell line and patient demographics in Table 2, which
is published as supporting information on the PNAS web site).
Patient ascites cells were obtained directly from the operating
theatre and analyzed within 96 h. We detected verapamil-sensitive
SP cells in IGROV-1 (Fig. 6A), OVCAR 3 (data not shown), and
SK-OV-3 (21), but not in OVCAR 8 (Fig. 6B). Viable human
ascites cells, selected as CD45??CD31?, were found to exhibit
verapamil-sensitive SP cells in four of six patients (Fig. 6 C and D).
primary ovarian cancer ascites cells possess SP cells.
Mouse and Human Ovarian Cancer Cell Surface Phenotype. To inves-
cell surface markers, as well as to identify differential expression
between SP and NSP cells, we analyzed mouse and human ovarian
cancer cells by flow cytometry. All mouse and human SP cells were
(platelet endothelial cell adhesion molecule 1?endothelial cells).
Compared with NSP cells, the MOVCAR 7 SP cells were enriched
in number of cells and intensity of expression of c-kit?CD117 (stem
tumor metastasis marker CD 44 (hyaluronic acid receptor),
vitro. MOVCAR 7 cells express the MISRII by
epifluorescent and confocal microscopy (A–
C). RT-PCR evaluation of SP cells demon-
pathway (D, left to right: SMAD 1, SMAD 5,
SMAD 8, MIS type I receptors Alk 2 and Alk 3,
sort by MTT assay (E) and demonstrate inhibi-
tion of both SP (86%) and NSP (93%) cells by
SP cells remain responsive to MIS (F, 93% in-
hibition; G, 94% inhibition). All experiments
were performed in triplicate.
MOVCAR 7 SP cells respond to MIS in
from patients have SPs and express the BCRP1 transporter.
Human ovarian cancer cell line IGROV-1 had a verapamil-
sensitive SP (A and E), whereas OVCAR-8 did not (B and F).
Human serous adenocarcinoma ascites patients 215 and 216
have small verapamil-sensitive SPs (C, D, G, and H). Immuno-
215 and 216 demonstrate colocalization of BCRP1 with
HoechstLowcells (I, K, and L; white arrows), whereas OVCAR-8
did not express HoechstLowor BCRP1-positive cells (J).
Human ovarian cancer cell lines and primary ascites
Szotek et al.
July 25, 2006 ?
vol. 103 ?
no. 30 ?
whereas 4306 cells and most human ovarian cancer cells do not.
MOVCAR 7 and 4306 SP and NSP cells did not express CD24,
CD34, CD105, CD133, or Sca-1 (Table 3, which is published as
supporting information on the PNAS web site). Human cell lines
and ascites cells showed variable expression of the epithelial cell
marker epithelial-specific antigen?Ep-CAM (epithelial specific an-
tigen) and CD24 (Table 2 and Fig. 8, which is published as
supporting information on the PNAS web site). These markers,
aside from c-kit in MOVCAR 7, did not add to the consistent SP
phenotype and Bcrp1 immunostaining we have observed in iden-
The hypothesis that rare ‘‘embryonic rests’’ are responsible for
in somatic stem cell identification has rejuvenated the investigation
of this premise (4, 27–29). The unique asymmetric self-renewal
capacities of somatic stem cells make it plausible and probable that
mutations in these cells are perpetuated and over time lead to
malignancy. Like somatic stem cells, cancer stem cells have the
properties of self-renewal, heterologous descendent cells, slow
cell-cycle times, and, unlike somatic stem cells, enriched tumor
formation (8, 24). Here we demonstrate these properties within a
subpopulation of mouse ovarian cancer cells that were isolated by
produce heterologous descendent NSP cells in culture, MOVCAR
7 SP cells are predominantly G1cell cycle arrested, and the in vivo
time to appearance of tumors in animals injected with equal
numbers of MOVCAR 7 cells may be shorter in those receiving SP
cells. We speculate that the number of SP cells required to initiate
tumor formation in vivo is likely quite low, as evidenced by the
appearance of tumors in NSP-injected animals at the same time as
animals injected with unsorted cells possessing approximately the
comparison with human ovarian cancer.
Ovarian cancer patients initially respond well to surgical
cytoreduction and chemotherapy. Chemotherapy alone can yield
several logs of tumor cytoreduction but seldom a cure. The
majority of patients who respond to primary chemotherapy
ultimately develop recurrent, usually drug-resistant, disease that
is conceivably due to the ability of ovarian cancer stem cells to
escape these drugs. BCRP1, otherwise known as the ABCG2
transporter, confers the ability to not only define a stem cell-like
Hoechst 33342-excluding SP but, perhaps more importantly, the
drug resistance-associated efflux of many lipophilic chemother-
apeutic agents such as mitoxantrone, daunorubicin, doxorubicin,
indolcarbazole, and others (22). Here we demonstrate that
candidate mouse ovarian cancer stem cells, defined as Hoechst-
effluxing, verapamil-sensitive, and BCRP1?SP cells, are more
resistant to doxorubicin, confirming these stem cell-like charac-
teristics as a potential mechanism for drug resistance. In addi-
tion, we identified a similar subpopulation of cells in both human
ovarian cancer cell lines and primary human ascites cells that
could be defined as Hoechst-effluxing, verapamil-sensitive,
BCRP1?SP cells. We propose that these ‘‘markers’’ might be
used to detect and isolate patient primary ovarian cancer stem
cells for further characterization.
We cannot with certainty assert that SP cells are cancer stem
cells; however, a subpopulation of cells found in the mouse SPs
of whether SP cancer cells are truly cancer stem cells or early
progenitor cells, expression of the drug-resistance transporter
BCRP1 or other multidrug-resistance proteins (30–33) may have a
profound impact on selection of individual treatment strategies,
clinical outcome, and the design or selection of the next generation
of chemotherapeutic agents. For example, the fact that MIS could
inhibit human anchorage-independent Mullerian tumors in soft
agarose (34) indicated that MIS might act on cancer stem cell-like
populations and led us to investigate its efficacy against these
candidate cancer stem cells. The evidence that MIS inhibits
MOVCAR 7 SP cells in vitro suggests that MIS has the potential to
function as an effective adjuvant to current ovarian cancer chemo-
therapeutic regimens because of its ability to attack this elusive
subpopulation of cancer cells. However, MIS inhibits MOVCAR 8
and OVCAR 8 (25, 35), indicating that response to MIS is not
dependent on the presence of an SP. Currently, the evaluation of
a wide range of chemotherapeutic and molecular-targeted agents
are tested in nonselected in vitro culture systems or animal xeno-
grafts with efficacy being scored on cell death of what is likely the
dominant, drug-sensitive, and perhaps biologically irrelevant NSP
development of effective therapeutic agents. Further work is
needed and underway to more clearly define primary human
ovarian cancer stem cells and their response to MIS in vivo.
Flow Cytometry. FlowcytometrywasperformedintheDepartment
of Pathology and Center for Regenerative Medicine Flow Cytom-
and human ovarian cancer SP sorting and immunophenotyping
were performed as described in Supporting Methods, which is
published as supporting information on the PNAS web site. When
testing SPs for multidrug resistance-like BCRP1 sensitivity, vera-
pamil (25–50 ?g?ml; Sigma) was also added.
For cell cycle analysis, MOVCAR 7 cells were harvested, sorted
for HoechstHighNSP, HoechstMid, and HoechstLowSP cells, and
fixed with 70% ethanol for 24 h. Cells were washed in PBS, stained
with 20 ?g?ml propidium iodide and 1 mg?ml RNase (Type IIA;
Sigma), and collected on a Life Sciences Research flow cytometer
configured with CELLQUEST PRO software (BD Biosciences, Frank-
lin Lakes, NJ).
Cell Lines and Culture. Mouse ovarian cancer cell lines, MOVCAR
7 and 8, were developed by D.C. by using the MISRII promoter
to drive the SV40 T antigen (19). The OVCAR 3 and OVCAR
8 human ovarian cancer cell lines were developed by Thomas
Hamilton (Fox Chase Cancer Center) (37). The 4306 cell line
was developed by D.M.D. from conditional LSL-K-rasG12D/??
PtenloxP/loxPmice after infection of ovarian surface epithelium
with adenovirus expressing Cre recombinase. These mice de-
veloped invasive endometrioid ovarian cancers 7 weeks after
infection, and the 4306 cell line was established from ascites cells
(20). IGROV-1 and SK-OV-3 were obtained from American
Type Culture Collection (ATCC). Cell lines were maintained in
1% penicillin?streptomycin, and 1% insulin-transferrin-
selenium (ITS; GIBCO) at 37°C, 5% CO2, in T175 flasks within
a humidified chamber. All cells recovered from sorting were
grown in the same media.
Human Primary Ascites Cell Isolation. Primary ascites cells were
analyzed from five stage III ovarian cancer patients and one
(AC-01) patient with recurrent ascites, who ranged in age from 54
to 71 years (mean, 62.2 years). The study was approved by the
Human Studies Committee of Massachusetts General Hospital
(Protocol No. FWA0003136), and consent was obtained from each
patient on the Gynecology Oncology Service at the time of
outpatient paracentesis or before surgery. Ascites harvested at
laparotomy or ultrasound-guided paracentesis were placed on ice,
centrifuged to isolate the cellular component, and resuspended in
media. Erythrocytes were lysed, and cells were cultured in RPMI
with 10% female FBS, 1% penicillin?streptomycin, and 1% fun-
gizome. Cells were analyzed by flow cytometry within 96 h for the
presence of an SP and surface markers.
www.pnas.org?cgi?doi?10.1073?pnas.0603672103Szotek et al.
Immunostaining of Cultured Cells. Anit-MISRII rabbit polyclonal Download full-text
antibodies (153p?MISRII) were developed for Western blot
analysis in the Pediatric Surgical Research Laboratories (35).
Immunofluorescence was performed on MOVCAR 7 and 4306
cells by using 153p as described (25). Images were obtained by
using either epifluorescent (Nikon Eclipse E400 microscope,
SPOT camera, and SPOT ADVANCE software) or confocal mi-
croscopy (Leica TCS NT confocal microscope, CONFOCAL soft-
ware Version 2.5 Build 1227, and krypton 568-nm laser; Leica,
For BCRP1 immunostaining, cells were double-labeled in sus-
pension with Hoechst 33342 and BCRP1 antibody as described in
ref. 5 and as detailed in Supporting Methods.
Reverse Transcriptase PCR. Total RNA from MOVCAR 7 and 4306
RNeasy Mini Kit (catalog no. 74104) according to the manufac-
cDNA by using Superscript II reverse transcriptase as directed by
with an annealing temperature of 57°C and separated on 2%
agarose gels. Mouse PCR primers are as in Table 4, which is
published as supporting information on the PNAS web site.
Growth Inhibition by MIS in Vitro. MTT assay was used to assess
proliferation inhibition. MOVCAR 7 and 4306 cells were har-
vested, sorted for SPs and NSPs, and plated in the inner wells of
96-well plates at 1,000 cells per well in 200 ?l of medium per well.
Twenty-four hours after plating, each set of 10 wells of SP or NSP
paclitaxel (6 mg?ml; NovaPlus, Irving, TX), a 4-nM doxorubicin
hydrochloride injection (2 mg?ml; NovaPlus), or media alone. At
day 5 or 7 of incubation, cell viability was quantified by measuring
mitochondrial activity (38) on an ELISA plate reader at an absor-
bance of 550 nm to generate an OD proportional to the relative
abundance of live cells in a given well.
Growth of MOVCAR 7 SP Cells in Vivo.MOVCAR7SPandNSPcells
were sorted and injected into T and B cell-deficient 6-week-old
female Swiss nude mice in equal numbers (first experiment, 5.0 ?
105; second experiment, 7.5 ? 105) into the dorsal fat pad between
the scapulae. Mice were housed in the Edwin L. Steele Laboratory
for Tumor Biology under American Association for Laboratory
Animal Science guidelines with the approval of the MGH Animal
Care and Use Committee (protocol no. 2005N000384).
Purification of Recombinant Human MIS. The human MIS gene was
transfected into CHO cells, amplified, purified, and maintained in
a dedicated facility in the Pediatric Surgical Research Laboratories
for use in this study as described in ref. 39. MIS levels were
measured by using human MIS-specific ELISA (40). MIS was
purified by a combination of lectin affinity chromatography and
FPLC anion-exchange chromatography (39). The MIS purified by
Statistical Analysis. In MTT assays, MIS-, doxorubicin-, and
paclitaxel-treated and untreated samples were analyzed by using
the univariant two-tailed Student t test, with P ? 0.05 conferring
statistical significance. All experiments were performed in
We thank Dr. Rakesh K. Jain for permitting us to perform the nude mice
experiments in the Edwin L. Steele Laboratory for Tumor Biology; Dr.
Thomas Flotte and Ms. Margaret E. Sherwood for guidance in perform-
ing confocal microscopy; Dr. Tyler Jacks for access to the 4306 cell line
Scadden for many suggestions and an internal review of the manuscript.
Human tissues were provided through the Ovarian Cancer Tumor Bank
at the Massachusetts General Hospital (MGH), supported by the
Dana–Farber Harvard Cancer Center Ovarian SPORE (1P50CA105009)
Cell Institute. P.P.S. is supported by Ruth L. Kirchstein National
Research Service Award T32 Training Grant in Cancer Biology
5T32CA071345-10. D.M.D. is supported by the Burroughs Wellcome
Fund Career Award. D.C. is supported by National Institutes of Health
(NIH) Grants P50 CA083638 and U01 CA084242. P.K.D. and D.T.M.
are supported by NIH Grants CA17393 and HD32112. D.T.M. is also
supported by the Edmund C. Lynch, Jr. Cancer Fund through Dr. Jeffrey
Gelfand. This work was also supported by contributions to the Pediatric
Surgical Research Laboratories from the McBride Family and the W.
Gerald Austen Funds.
1. Al-Hajj, M., Wicha, M. S., Benito-Hernandez, A., Morrison, S. J. & Clarke, M. F.
(2003) Proc. Natl. Acad. Sci. USA 100, 3983–3988.
2. Haraguchi, N., Utsunomiya, T., Inoue, H., Tanaka, F., Mimori, K., Barnard, G. F. &
Mori, M. (2006) Stem Cells (Dayton, Ohio) 24, 506–513.
3. Kondo, T., Setoguchi, T. & Taga, T. (2004) Proc. Natl. Acad. Sci. USA 101, 781–786.
4. Wulf, G. G., Wang, R. Y., Kuehnle, I., Weidner, D., Marini, F., Brenner, M. K.,
Andreeff, M. & Goodell, M. A. (2001) Blood 98, 1166–1173.
5. Seigel, G. M., Campbell, L. M., Narayan, M. & Gonzalez-Fernandez, F. (2005) Mol.
Vis. 11, 729–737.
6. Poste, G. & Greig, R. (1982) Invasion Metastasis 2, 137–176.
7. Poste, G., Tzeng, J., Doll, J., Greig, R., Rieman, D. & Zeidman, I. (1982) Proc. Natl.
Acad. Sci. USA 79, 6574–6578.
8. Reya, T., Morrison, S. J., Clarke, M. F. & Weissman, I. L. (2001) Nature 414, 105–111.
9. Tu, S. M., Lin, S. H. & Logothetis, C. J. (2002) Lancet Oncol. 3, 508–513.
10. Li, L. & Xie, T. (2005) Annu. Rev. Cell Dev. Biol. 21, 605–631.
11. Bukovsky, A., Caudle, M. R., Svetlikova, M. & Upadhyaya, N. B. (2004) Reprod. Biol.
Endocrinol. 2, 20.
12. Scully, R. E. (1970) Hum. Pathol. 1, 73–98.
13. Young, R. H. (2005) Mod. Pathol. 18 2, S3–S17.
14. Jemal, A., Murray, T., Ward, E., Samuels, A., Tiwari, R. C., Ghafoor, A., Feuer, E. J.
& Thun, M. J. (2005) CA Cancer J. Clin. 55, 10–30.
15. Cannistra, S. A. (1993) N. Engl. J. Med. 329, 1550–1559.
16. Parker, S. L., Tong, T., Bolden, S. & Wingo, P. A. (1997) CA Cancer J. Clin. 47, 5–27.
17. Gottesman, M. M., Fojo, T. & Bates, S. E. (2002) Nat. Rev. Cancer 2, 48–58.
18. Goodell, M. A., Brose, K., Paradis, G., Conner, A. S. & Mulligan, R. C. (1996) J. Exp.
Med. 183, 1797–1806.
19. Connolly, D. C., Bao, R., Nikitin, A. Y., Stephens, K. C., Poole, T. W., Hua, X.,
20. Dinulescu, D. M., Ince, T. A., Quade, B. J., Shafer, S. A., Crowley, D. & Jacks, T.
(2005) Nat. Med. 11, 63–70.
21. Hirschmann-Jax, C., Foster, A. E., Wulf, G. G., Nuchtern, J. G., Jax, T. W., Gobel,
U., Goodell, M. A. & Brenner, M. K. (2004) Proc. Natl. Acad. Sci. USA 101,
22. Doyle, L. A. & Ross, D. D. (2003) Oncogene 22, 7340–7358.
23. Gottesman, M. M. & Pastan, I. (1993) Annu. Rev. Biochem. 62, 385–427.
24. Sell, S. (2004) Crit. Rev. Oncol. Hematol. 51, 1–28.
25. Pieretti-Vanmarcke, R., Donahoe, P. K., Szotek, P., Manganaro, T., Lorenzen, M. K.,
Lorenzen, J., Connolly, D. C., Halpern, E. F. & MacLaughlin, D. T. (2006) Clin.
Cancer Res. 12, 1593–1598.
26. Zhan, Y., Fujino, A., MacLaughlin, D., Manganaro, T., Szotek, P., Arango, N.,
Teixeira, J. & Donahoe, P. (2006) Development (Cambridge, U.K.) 133, 2359–2369.
27. Behbod, F. & Rosen, J. M. (2005) Carcinogenesis 26, 703–711.
28. Gale, R. P. & Butturini, A. (1992) Leukemia 6, Suppl. 1, 80–85.
29. Makino, S. (1956) Ann. N. Y. Acad. Sci. 63, 818–830.
30. Duan, Z., Brakora, K. A. & Seiden, M. V. (2004) Mol. Cancer Ther. 3, 833–838.
31. Duan, Z., Lamendola, D. E., Yusuf, R. Z., Penson, R. T., Preffer, F. I. & Seiden,
M. V. (2002) Anticancer Res. 22, 1933–1941.
32. Penson, R. T., Oliva, E., Skates, S. J., Glyptis, T., Fuller, A. F., Jr., Goodman, A. &
Seiden, M. V. (2004) Gynecol. Oncol. 93, 98–106.
33. Seiden, M. V., Swenerton, K. D., Matulonis, U., Campos, S., Rose, P., Batist, G., Ette,
E., Garg, V., Fuller, A., Harding, M. W. & Charpentier, D. (2002) Gynecol. Oncol.
34. Fuller, A. F., Jr., Krane, I. M., Budzik, G. P. & Donahoe, P. K. (1985) Gynecol. Oncol.
35. Ha, T. U., Segev, D. L., Barbie, D., Masiakos, P. T., Tran, T. T., Dombkowski, D.,
Glander, M., Clarke, T. R., Lorenzo, H. K., Donahoe, P. K. & Maheswaran, S. (2000)
J. Biol. Chem. 275, 37101–37109.
36. Preffer, F. I., Dombkowski, D., Sykes, M., Scadden, D. & Yang, Y. G. (2002) Stem
Cells (Dayton, Ohio) 20, 417–427.
37. Schilder, R. J., Hall, L., Monks, A., Handel, L. M., Fornace, A. J., Jr., Ozols, R. F.,
Fojo, A. T. & Hamilton, T. C. (1990) Int. J. Cancer 45, 416–422.
38. Denizot, F. & Lang, R. (1986) J. Immunol. Methods 89, 271–277.
39. Lorenzo, H. K., Teixeira, J., Pahlavan, N., Laurich, V. M., Donahoe, P. K. &
MacLaughlin, D. T. (2002) J. Chromatogr. B Biomed. Sci. Appl. 766, 89–98.
40. Hudson, P. L., Dougas, I., Donahoe, P. K., Cate, R. L., Epstein, J., Pepinsky, R. B.
& MacLaughlin, D. T. (1990) J. Clin. Endocrinol. Metab. 70, 16–22.
41. Donahoe, P. K., Ito, Y., Marfatia, S. & Hendren, W. H. (1976) Biol. Reprod. 15,
42. Donahoe, P. K., Ito, Y. & Hendren, W. H. (1977) J. Surg. Res. 23, 141–148.
Szotek et al.
July 25, 2006 ?
vol. 103 ?
no. 30 ?